121 related articles for article (PubMed ID: 3146749)
1. UVB-induced melanocyte proliferation and 5-S-cysteinyldopa excretion in dysplastic nevus syndrome.
Stierner U; Augustsson A; Rosdahl I; Kågedal B; Suurküla M
Photodermatol; 1988 Oct; 5(5):218-23. PubMed ID: 3146749
[TBL] [Abstract][Full Text] [Related]
2. Melanocytes, moles and melanoma--a study on UV effects.
Stierner U
Acta Derm Venereol Suppl (Stockh); 1991; 168():1-31. PubMed ID: 1814138
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of 5-S-cysteinyldopa in relation to skin type, UVB-induced erythema, and melanocyte proliferation in human skin.
Stierner U; Rosdahl I; Augustsson A; Kågedal B
J Invest Dermatol; 1988 Nov; 91(5):506-10. PubMed ID: 3139773
[TBL] [Abstract][Full Text] [Related]
4. Identification of 5-S-cysteinyldopa by high performance liquid chromatography in biopsies from patients with dysplastic melanocytic nevi.
Halldin MM; Cook WS; Kawashima T; Crutcher WA; Fukuyama K
Cancer Res; 1987 Jan; 47(2):636-8. PubMed ID: 3098416
[TBL] [Abstract][Full Text] [Related]
5. 5-S-Cysteinyldopa and dopa in serum during treatment with 8-methoxypsoralen and UVA light.
Hansson C; Rorsman H; Rosengren E; Tegner E
Acta Derm Venereol; 1981; 61(3):251-5. PubMed ID: 6167110
[TBL] [Abstract][Full Text] [Related]
6. Urinary 5-S-cysteinyldopa in Parkinsonism after DOPA and carbidopa.
Stewart RM; Miller S; Gunder M
Acta Derm Venereol; 1983; 63(2):97-101. PubMed ID: 6189350
[TBL] [Abstract][Full Text] [Related]
7. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
8. 5-S-cysteinyldopa excretion after treatment with 8-methoxypsoralen and UVA light.
Agrup G; Hansson C; Rorsman H; Rosengren A-M ; Rosengren E; Tegner E
J Invest Dermatol; 1978 Jan; 70(1):25-6. PubMed ID: 618976
[TBL] [Abstract][Full Text] [Related]
9. Melanocyte mitosis in UVB-irradiated mouse skin.
Rosdahl IK
Acta Derm Venereol; 1978; 58(3):217-21. PubMed ID: 78635
[TBL] [Abstract][Full Text] [Related]
10. The recognition of UV-irradiation melanocyte with HMB-45 monoclonal antibody.
Cheng H; Sun GJ; Thiele B; Wolff HH
Chin Med J (Engl); 1994 Mar; 107(3):225-9. PubMed ID: 8088186
[TBL] [Abstract][Full Text] [Related]
11. [Biochemical diagnoses of malignant melanomas with determinations of 5-S-cysteinyldopa in lesions].
Sameshima T; Morishima T
Nihon Hifuka Gakkai Zasshi; 1989 May; 99(6):665-72. PubMed ID: 2511358
[TBL] [Abstract][Full Text] [Related]
12. Urinary excretion of 5-S-cysteinyldopa is enhanced by PUVA and is independent of skin type.
Tardy J; Barrois JP; Bendelac A; Leonard F; Triller R; Jardillier JC; Kalis B
Photodermatol; 1987 Aug; 4(4):205-8. PubMed ID: 3124084
[TBL] [Abstract][Full Text] [Related]
13. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
14. Serum 5-S-cysteinyldopa levels in patients with psoriasis undergoing narrowband ultraviolet B phototherapy.
Kikuchi K; Wakamatsu K; Tada Y; Komine M; Ito S; Tamaki K
Clin Exp Dermatol; 2008 Nov; 33(6):750-3. PubMed ID: 18954414
[TBL] [Abstract][Full Text] [Related]
15. 5-S-cysteinyldopa and pigment response to UVA light.
Tegner E; Rorsman H; Rosengren E
Acta Derm Venereol; 1983; 63(1):21-5. PubMed ID: 6191484
[TBL] [Abstract][Full Text] [Related]
16. Local and systemic effects on the epidermal melanocyte population in UV-irradiated mouse skin.
Rosdahl IK
J Invest Dermatol; 1979 Oct; 73(4):306-9. PubMed ID: 479635
[TBL] [Abstract][Full Text] [Related]
17. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
[TBL] [Abstract][Full Text] [Related]
18. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects.
Peterson LL; Woodward WR; Fletcher WS; Palmquist M; Tucker MA; Ilias A
J Am Acad Dermatol; 1988 Sep; 19(3):509-15. PubMed ID: 3139723
[TBL] [Abstract][Full Text] [Related]
19. Comet assay demonstrates a higher ultraviolet B sensitivity to DNA damage in dysplastic nevus cells than in common melanocytic nevus cells and foreskin melanocytes.
Noz KC; Bauwens M; van Buul PP; Vrolijk H; Schothorst AA; Pavel S; Tanke HJ; Vermeer BJ
J Invest Dermatol; 1996 Jun; 106(6):1198-202. PubMed ID: 8752657
[TBL] [Abstract][Full Text] [Related]
20. [5-S-cysteinyldopa in the urine - a "tumor test" for malignant melanoma? Comparison with the usual laboratory examinations].
Paul E; Graef V; Ruppel R
Z Hautkr; 1980 Dec; 55(23):1543-60. PubMed ID: 6782780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
